A comparison of perceptions of 'modern-type' and melancholic depression in Japan.

Int J Soc Psychiatry

2 Institute of Humanities and Social Sciences, College of Humanities and Sciences, Nihon University, Tokyo, Japan.

Published: November 2016

Background: In Japan, psychiatrists have noted two different types of depression, traditional/melancholic depression and 'modern-type' depression (MTD). Although both the modern and the traditional types of depression overlap in regard to symptoms, these are two distinct syndromes, which can lead to confusion for Japanese people.

Aims: This study aims to examine impressions of two types of depression using vignettes and clarify the differences in perceptions of the two types.

Methods: The participants, 206 Japanese undergraduates, were presented with two vignettes, one describing a patient with traditional-type depression and the other describing a patient with MTD, and then were asked to answer questions regarding their perceptions of the patient. In order to control covariates (i.e. perceived severity and dysfunction of depression), analyses of covariance with repeated measures were administered.

Results: People generally had more negative perceptions of the patient with MTD. For example, when the protagonist was the patient with MTD, people were more likely to avoid and less motivated to support the patient. Large differences were also found in causal attribution to internal and controllable causes.

Conclusion: Negative impressions of the patient with MTD may be partly explained by causal attribution to internal and controllable factors.

Download full-text PDF

Source
http://dx.doi.org/10.1177/0020764016665410DOI Listing

Publication Analysis

Top Keywords

patient mtd
16
types depression
12
depression
8
describing patient
8
perceptions patient
8
causal attribution
8
attribution internal
8
internal controllable
8
patient
7
mtd
5

Similar Publications

Homozygous MTAP deletion occurs in ~15% of cancers, making them vulnerable to decreases in the concentration of S-adenosylmethionine (SAM). AG-270/S095033 is an oral, potent, reversible inhibitor of methionine adenosyltransferase 2 A (MAT2A), the enzyme primarily responsible for the synthesis of SAM. We report results from the first-in-human, phase 1 trial of AG-270/S095033 as monotherapy in patients with advanced malignancies (ClinicalTrials.

View Article and Find Full Text PDF

Efficacy and safety of multi-target tyrosine kinase inhibitor AL2846 combined with gemcitabine in pancreatic cancer.

Invest New Drugs

January 2025

Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Tianjin Key Laboratory of Digestive Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, China.

Pancreatic cancer patients urgently need new treatments, and we explored the efficacy and safety of combination therapy with AL2846 and gemcitabine in pancreatic cancer patients. This was a single-arm, single-center, open-label phase I/IIa study (NCT06278493). The dose-escalation phase was designed to evaluate the maximum tolerated dose (MTD) of AL2846 combined with gemcitabine.

View Article and Find Full Text PDF

GT103 is a first-in-class, fully human, IgG3 monoclonal antibody targeting complement factor H that kills tumor cells and promotes anti-cancer immunity in preclinical models. We conducted a first-in-human phase 1b study dose escalation trial of GT103 in refractory non-small cell lung cancer to assess the safety of GT103 (NCT04314089). Dose escalation was performed using a "3 + 3" schema with primary objectives of determining safety, tolerability, PK profile and maximum tolerated dose (MTD) of GT103.

View Article and Find Full Text PDF

This study (NCT04728035) aimed to explore the safety and efficacy of liposomal irinotecan (HE072) in patients with metastatic triple-negative breast cancer (mTNBC). This study consisted of two parts. In part 1, the 3 + 3 design was used to investigate three dose levels of HE072 (50, 70 and 90 mg/m).

View Article and Find Full Text PDF

Background: Radiation segmentectomy (RS) is an alternative potential local curative treatment for selected colorectal liver metastases (CLMs) not amenable to ablation or limited resection.

Purpose: The aim of this study was to evaluate the dosimetric response of low volume CLMs to RS in heavily pretreated patients who are not candidates for resection or percutaneous ablation.

Patients And Methods: This single-center retrospective study evaluated CLMs patients treated with RS (prescribed tumor dose >190 Gy) from 2015 to 2023.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!